# Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

> **NCT04040075** · PHASE4 · TERMINATED · sponsor: **Southampton Healthcare, Inc.** · enrollment: 12 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Biktarvy Tab

## Key facts

- **NCT ID:** NCT04040075
- **Lead sponsor:** Southampton Healthcare, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-01
- **Primary completion:** 2022-06-14
- **Final completion:** 2022-07-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Unable to complete enrollment goals due to unanticipated factors of screen failures, covid pandemic, and continued staffing and enrollment difficulties
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040075, "Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04040075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*